Stockscreener 앱 받기
0.4986
0.08%
-0.0004
시간 외 거래:
.50
0.0014
+0.28%
전일 마감가:
$0.499
열려 있는:
$0.49
하루 거래량:
4.40M
Relative Volume:
0.75
시가총액:
$76.47M
수익:
-
순이익/손실:
$-56.85M
주가수익비율:
-0.3198
EPS:
-1.559
순현금흐름:
-
1주 성능:
+5.03%
1개월 성능:
+24.65%
6개월 성능:
-45.97%
1년 성능:
-68.64%
1일 변동 폭
$0.48
$0.5063
1주일 범위
$0.455
$0.524
52주 변동 폭
$0.3772
$3.03
Fractyl Health Inc Stock (GUTS) Company Profile
명칭
Fractyl Health Inc
전화
781-902-8800
주소
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.4986 | 76.53M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-28 | 개시 | Ladenburg Thalmann | Buy |
| 2024-02-28 | 개시 | Evercore ISI | Outperform |
| 2024-02-27 | 개시 | BofA Securities | Buy |
| 2024-02-27 | 개시 | Morgan Stanley | Overweight |
모두보기
Fractyl Health Inc 주식(GUTS)의 최신 뉴스
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
GUTS Technical Analysis & ETF Price Forecast - Intellectia AI
GUTS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fractyl Health Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Fractyl Health completes randomization in Remain-1 pivotal cohort of Revita® - marketscreener.com
Fractyl Completes Randomization in REMAIN-1 Revita Trial - TipRanks
Fractyl Health Completes Randomization In Remain-1 Pivotal Cohort Of Revita® - TradingView
Fractyl Health completes randomization in REMAIN-1; topline 6-month data due early Q4 2026 - TradingView
Fractyl Health (GUTS) hits Revita pivotal trial milestone, eyes 2026 FDA filing - Stock Titan
Fractyl trial tests Revita to prevent weight regain after GLP-1 drugs - Stock Titan
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance - Bitget
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Should I buy Fractyl Health, Inc. (GUTS) - Zacks Investment Research
What is the PEG ratio of Fractyl Health Inc.July 2025 Technicals & Expert-Curated Trade Recommendations - mfd.ru
Alyeska discloses 4.97% Fractyl Health (GUTS) stake in ownership filing - Stock Titan
Fractyl Health plummets on data for Revita for weight loss maintenance - MSN
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6% - MarketBeat
Insider Sell: What is the dividend yield of Fractyl Health IncJuly 2025 Final Week & AI Driven Price Predictions - baoquankhu1.vn
Decliners Report: How correlated is Fractyl Health Inc to the S P5002025 Momentum Check & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Technicals: Does Fractyl Health Inc have pricing powerJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Even endpoint hits don’t spare shares in three weight-loss updates - BioCentury
Why Fractyl Health Inc. stock remains a top recommendationJuly 2025 Recap & Expert Approved Trade Ideas - mfd.ru
Market Trends: Is Fractyl Health Inc benefiting from interest rate changesJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Pricey healthcare stocks with halting momentumlow momentum and high valuation (AIM:NYSE) - Seeking Alpha
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts - Seeking Alpha
Why did GUTS stock plummet today despite positive gut therapy midterm study? - MSN
Fractyl Health (GUTS) Is Down 78.0% After Positive REMAIN-1 Midpoint Data And De Novo FDA PlanHas The Bull Case Changed? - simplywall.st
Fractyl Health Shares Fall After Morgan Stanley Downgrade - marketscreener.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Fractyl Health, Inc. Investigated on Behalf of InvestorsContact the DJS Law Group to Discuss Your Rights – GUTS - marketscreener.com
Institutional Owners May Take Dramatic Actions as Fractyl Health, Inc.'s (NASDAQ:GUTS) Recent 72% Drop Adds to One-year Losses - 富途牛牛
Fractyl Health (GUTS) Tests Whether Revita Can Redefine Post-GLP-1 Weight Maintenance Economics - Yahoo Finance
Revita treatment shows promise for weight maintenance after GLP-1 use By Investing.com - Investing.com South Africa
Morgan Stanley downgrades Fractyl Health stock rating to Equalweight on Revita trial results By Investing.com - Investing.com South Africa
Morgan Stanley downgrades Fractyl Health stock rating to Equalweight on Revita trial results - Investing.com India
What if Oprah Knew About Fractyl Health? - MedCity News
Why Is Fractyl Health Stock Tumbling Today?Fractyl Health (NASDAQ:GUTS) - Benzinga
Fractyl Health's Revita reduces post-GLP-1 weight regain by ~70% - TechTarget
Crude Oil Surges 3%; Caterpillar Shares Gain After Q4 Results - Benzinga
Fractyl Health announces compelling 6-month randomized Remain-1 midpoint data showing durable weight maintenance with Revita after GLP-1 discontinuation - marketscreener.com
Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Fractyl’s Revita reduces post-GLP-1 weight regain 70% - BioWorld MedTech
GUTS: Revita cut post-GLP-1 weight regain by 70% in high-risk patients at six months, with strong safety - TradingView
US Stocks Mixed; Tesla Posts Upbeat Q4 Earnings - Benzinga
Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? - Stocktwits
GUTS: Revita shows robust six-month weight maintenance post-GLP-1, supporting pivotal study success - TradingView
Fractyl Health Advances Revita for Post-GLP-1 Weight Maintenance - TipRanks
Fractyl Health Inc (GUTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):